Abin da ya kamata ka sani game da wannan magani mai karfi
Ga wani tare da sake dawowa-yad da ƙwayar sclerosis (RRMS) wanda ke fama da sake dawowa da bayyanar cututtuka, jima- magani shine yawan corticosteroid. Wadannan kwayoyi ne da suke nuna kama da wani hormone wanda ke samar da ƙananan jiki (redness, busa, zafi). A cikin yanayin da MS ya sake dawowa, corticosteroids rage ƙonawa a cikin mummunan tsarin-ƙonawa wanda ke haifar da bayyanar cutar MS kamar su ciwon ido ko matsalolin hangen nesa , rauni na tsoka, da matsala ta daidaitawa.
Kuna Bukatar Solu-Medrol?
Sau da yawa, corticosteroid na zabi don magance magunguna mai tsanani MS shine magani da ake kira Solu-Medrol (methylprednisolone). (Lura cewa wani lokaci likita zai rubuta wannan magani don mutumin da yake da alamar bayyanar cutar kamar irin ciwo da ke ci gaba da tsanantawa da tsawon lokaci, ya ci gaba har zuwa maƙasudin zama maras tabbas, kuma bai samu mafi alhẽri tare da wasu jiyya ba.)
Solu-Medrol wani magani mai karfi ne, kuma ba haka ba ne ba tare da tasiri ba, don haka yana da muhimmanci a tabbatar da cewa yana da muhimmanci. Alal misali, yana buƙatar ya bayyana cewa ainihin sake dawowa MS yana ci gaba. Idan kun yi tunanin cewa yana iya faruwa a gare ku, ga wasu abubuwa da za ku tambayi kanku game da abin da kuke fuskanta. Idan ka amsa a wa annan tambayoyin, zaka iya samun sake dawowa.
- Shin ina samun sabon bayyanar cututtuka ko kuma bayyanar cututtuka na riga na ci gaba da muni?
- Shin wannan yana faruwa ne a cikin sa'o'i 24 zuwa kwanaki biyu?
- Shin waɗannan bayyanar cututtuka sun kasance fiye da awa 24?
- Shin ya kasance akalla wata daya tun lokacin da na dawo? (A wasu kalmomi, suna da alamun wariyar launin fata ba sun kasance ba ko barga don akalla kwanaki 30 kafin su bayyana ko sun kara muni?)
Don tabbatar da cewa kuna da sake dawowa ko kuma ku yi mulki, likita zai iya yin MRI. Ya bayyana cewa mutane da yawa tare da MS, musamman ma waɗanda suke cikin farkon matakan RRMS, suna da ƙananan raunuka masu aiki da suke faruwa a duk tsawon lokacin.
Waɗannan su ne raunuka da "haskakawa" a gaban gadolinium (wani wakili mai bambanci da aka yi amfani da shi na MRI) don kimanin makonni shida, sa'an nan kuma ya mutu kamar yadda ƙonewa ya ɗauka. Lokacin da MRI ya nuna irin waɗannan nau'in irin wannan cuta suna haifar da alamun bayyanar cututtuka, kuma ba lallai basa haifar da bayyanar cututtuka ba don amfani da kalmar "sake komawa" zuwa yanayin, Sulu-Medrol bazai buƙata ba.
Shan Sulu-Medrol
Lokacin da aka ba wannan magani don magance magungunan MS, ana ba da shi a cikin intravenously - wato, ta hanyar wani allura kai tsaye a cikin wani ɓangare na tsawon kwanaki uku zuwa biyar. Ga mutane da yawa, Solu-Medrol zai iya kawo taimako mai yawa daga sake dawowa. Wadansu sun gano cewa bayan an jima daya daga cikin miyagun ƙwayoyi, alamun MS waɗanda suke da lalacewa suna iya yin amfani da su, ko kuma sun ɓace gaba daya. A kalla, a cikin kwanaki biyu ko uku na Solu-Medrol mafi yawan mutane sunyi rahoton cewa alamun su sun fi kyau.
Ko da kuwa abin da ake amfani dashi, Solu-Medrol ba tare da illa masu lalacewa ba, irin su matsalolin jima'i da wadata, don haka a wasu lokuta zai zama mafi alhẽri a dakatar da sake dawowa (idan zaka iya jure wa bayyanar cututtuka ko samun taimako daga wani magani ). Ta hanyar karbar Solu-Medrol ba za ku kasance cikin haɗari na lalacewa ko lalacewa ta hanyar sake dawowa ba, kuma za ku guje wa sakamako masu illa.
Kuna iya tambayi likita game da ɗaukar Solu-Medrol a cikin takarda, maimakon ta jiko, wanda zai iya yankewa a kan sakamako masu illa. Akwai bincike na farko don nuna cewa methylprednisolone na iya zama kamar yadda tasiri a sauƙaƙe sakon MS ɗin a matsayin infusions.
> Sources:
> Ba Page, et al. "Ƙarfafawa da Tsaro na maganganun maganganu mai zurfi-Matsayi Methylprednisolone a cikin Sauye-sauyen Sclerosis, Wani Gwajin Zuciya Biyu (COPOUSEP)." Lancet . 2015 Satumba 5; 386 (9997): 974-81.
> Olek MJ. "Gudanar da Ayyukan Ƙwarewar Ƙwararrun Sclerosis a cikin Manya." UpToDate 2016.
> Ontaneda D & Rae-Grant AD. Gudanar da Ayyukan Ƙarshe mai Girma a Multiple Sclerosis. Ann Indian Acad Neurol . 2009 Oktoba; 12 (4): 264-7.